Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

[1]  J. Dungan.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[2]  A. Ashworth,et al.  BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. , 2010, Cell stem cell.

[3]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[4]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[5]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Tan,et al.  Triple Negative Breast Cancer: Outcome Correlation With Immunohistochemical Detection of Basal Markers , 2010, The American journal of surgical pathology.

[7]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[8]  W. Foulkes,et al.  Tumor size and survival in breast cancer—a reappraisal , 2010, Nature Reviews Clinical Oncology.

[9]  Jan Lubinski,et al.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Badve.  Does tumor size trump biology? , 2010, Clinical breast cancer.

[11]  A. Ashworth,et al.  Breast cancer molecular profiling with single sample predictors: a retrospective analysis. , 2010, The Lancet. Oncology.

[12]  T. Nielsen,et al.  Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Reis-Filho,et al.  Adenoid cystic carcinomas of the breast and salivary glands (or ‘The strange case of Dr Jekyll and Mr Hyde’ of exocrine gland carcinomas) , 2010, Journal of Clinical Pathology.

[14]  Jorge S Reis-Filho,et al.  The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade , 2010, The Journal of pathology.

[15]  B. Kreike,et al.  The molecular underpinning of lobular histological growth pattern: a genome‐wide transcriptomic analysis of invasive lobular carcinomas and grade‐ and molecular subtype‐matched invasive ductal carcinomas of no special type , 2010, The Journal of pathology.

[16]  A. Jara-Lazaro,et al.  Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer , 2010, Modern Pathology.

[17]  R. Kennedy,et al.  BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer , 2010, Breast Cancer Research and Treatment.

[18]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[19]  Zihua Hu,et al.  Insight into microRNA regulation by analyzing the characteristics of their targets in humans , 2009, BMC Genomics.

[20]  Alan Mackay,et al.  Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma , 2009, Histopathology.

[21]  J. Reis-Filho,et al.  Histological and molecular types of breast cancer: is there a unifying taxonomy? , 2009, Nature Reviews Clinical Oncology.

[22]  A. Simpson,et al.  CT-X antigen expression in human breast cancer , 2009, Proceedings of the National Academy of Sciences.

[23]  J. Reis-Filho,et al.  Microarray-based Gene Expression Profiling as a Clinical Tool for Breast Cancer Management: Are We There Yet? , 2009, International journal of surgical pathology.

[24]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.

[25]  Nicholas J. Wang,et al.  Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. , 2009, Cancer research.

[26]  S. Lakhani,et al.  Molecular Evidence for Progression of Microglandular Adenosis (MGA) to Invasive Carcinoma , 2009, The American journal of surgical pathology.

[27]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Vincent-Salomon,et al.  Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum , 2009, Modern Pathology.

[29]  P. Argani,et al.  Most Basal-like Breast Carcinomas Demonstrate the Same Rb−/p16+ Immunophenotype as the HPV-related Poorly Differentiated Squamous Cell Carcinomas Which They Resemble Morphologically , 2009, The American journal of surgical pathology.

[30]  B. Gusterson.  Do 'basal-like' breast cancers really exist? , 2009, Nature Reviews Cancer.

[31]  J. O’Shaughnessy,et al.  Triple negative breast cancer: a phase 2, multi-center, open-label, randomized trial of gemcitabine/carboplatin (G/C), with or without BSI-201, a PARP inhibitor. , 2009 .

[32]  I. Ellis,et al.  Triple‐negative/basal‐like breast cancer: review , 2009, Pathology.

[33]  J. Reis-Filho,et al.  The role of molecular analysis in breast cancer , 2009, Pathology.

[34]  G. Azabdaftari,et al.  Refinement of breast cancer classification by molecular characterization of histological special types , 2009 .

[35]  D. Han,et al.  Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. , 2009, Cancer research.

[36]  Lodewyk F. A. Wessels,et al.  Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response , 2009, Breast Cancer Research and Treatment.

[37]  M. Gerstein,et al.  RNA-Seq: a revolutionary tool for transcriptomics , 2009, Nature Reviews Genetics.

[38]  B. Kreike,et al.  Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis , 2009, Breast Cancer Research and Treatment.

[39]  I. Ellis,et al.  Patho-biological aspects of basal-like breast cancer , 2009, Breast Cancer Research and Treatment.

[40]  Charles M. Perou,et al.  Triple-Negative Breast Cancer: Risk Factors to Potential Targets , 2008, Clinical Cancer Research.

[41]  J. Reis-Filho,et al.  Breast cancer special types: why bother? , 2008, The Journal of pathology.

[42]  Carlos Caldas,et al.  A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer , 2008, Breast Cancer Research.

[43]  P. Sánchez‐Rovira,et al.  Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[44]  D. Dabbs,et al.  CK5 is more sensitive than CK5/6 in identifying the "basal-like" phenotype of breast carcinoma. , 2008, American journal of clinical pathology.

[45]  Heidi Ledford,et al.  The death of microarrays? , 2008, Nature.

[46]  Carlos Caldas,et al.  A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer , 2008, Breast Cancer Research.

[47]  Gianluca Bontempi,et al.  Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.

[48]  G. Colditz,et al.  Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer , 2008, Breast Cancer Research.

[49]  Alan Ashworth,et al.  A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  J. Reis-Filho,et al.  Nestin is expressed in basal-like and triple negative breast cancers , 2008, Journal of Clinical Pathology.

[51]  Daniel Birnbaum,et al.  How basal are triple‐negative breast cancers? , 2008, International journal of cancer.

[52]  J. Shendure.  The beginning of the end for microarrays? , 2008, Nature Methods.

[53]  I. Ellis,et al.  Impact of Basal-Like Breast Carcinoma Determination for a More Specific Therapy , 2008, Pathobiology.

[54]  S. Johnston,et al.  Platinum-based chemotherapy in triple-negative breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  Ian O Ellis,et al.  Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  J. Benítez,et al.  Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes , 2008, Oncogene.

[57]  Y. Murakumo,et al.  CD109 expression in basal‐like breast carcinoma , 2008, Pathology international.

[58]  John W M Martens,et al.  Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.

[59]  N. Sneige,et al.  Clinical, Histopathologic, and Immunohistochemical Features of Microglandular Adenosis and Transition Into In Situ and Invasive Carcinoma , 2008, The American journal of surgical pathology.

[60]  C. Reynolds,et al.  Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy , 2008, Molecular Cancer Therapeutics.

[61]  J. Thiery,et al.  Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast , 2008, Clinical Cancer Research.

[62]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Sa A. Wang,et al.  The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset? , 2008, Human pathology.

[64]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[65]  J. Moyano,et al.  AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. , 2008, Annals of diagnostic pathology.

[66]  I. Ellis,et al.  Are Triple-Negative and Basal-Like Breast Cancer Synonymous? , 2008, Clinical Cancer Research.

[67]  A. Tutt,et al.  Triple negative tumours: a critical review , 2007, Histopathology.

[68]  M. J. van de Vijver,et al.  Immunohistochemical categorisation of ductal carcinoma in situ of the breast , 2007, British Journal of Cancer.

[69]  Robin L. Jones,et al.  Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients , 2008, Breast Cancer Research and Treatment.

[70]  Robin L. Jones,et al.  Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis , 2008, Breast Cancer Research and Treatment.

[71]  T. Nielsen,et al.  Are triple-negative tumours and basal-like breast cancer synonymous? , 2007, Breast Cancer Research.

[72]  F. Couch,et al.  Response: Re: Molecular Basis for Estrogen Receptor α Deficiency in BRCA1-Linked Breast Cancer , 2007 .

[73]  Karla Kerlikowske,et al.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. , 2007, Cancer cell.

[74]  E. Lerma,et al.  Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas) , 2007, Modern Pathology.

[75]  W. Han,et al.  Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer , 2007, BMC Cancer.

[76]  Harry Bartelink,et al.  Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas , 2007, Breast Cancer Research.

[77]  N. Sneige,et al.  Breast carcinoma arising in microglandular adenosis: a review of the literature. , 2007, Archives of pathology & laboratory medicine.

[78]  A. Rosenberg,et al.  Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients , 2007, Cancer.

[79]  I. Ellis,et al.  An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer , 2007, Genome Biology.

[80]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[81]  Marc Tischkowitz,et al.  Use of immunohistochemical markers can refine prognosis in triple negative breast cancer , 2007, BMC Cancer.

[82]  Y. Murakumo,et al.  CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells , 2007, Pathology international.

[83]  R. Cress,et al.  Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.

[84]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[85]  Potential chemotherapy options in the triple negative subtype of breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  A. Ashworth,et al.  BRCA1 dysfunction in sporadic basal-like breast cancer , 2007, Oncogene.

[87]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[88]  F. Couch,et al.  Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. , 2007, Journal of the National Cancer Institute.

[89]  Ian O Ellis,et al.  Prognostic markers in triple‐negative breast cancer , 2007, Cancer.

[90]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[91]  A. Vincent-Salomon,et al.  Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity , 2007, Breast Cancer Research.

[92]  M. Fernö,et al.  Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers , 2007, Breast Cancer Research.

[93]  D. Easton,et al.  Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival , 2007, Breast Cancer Research.

[94]  J. Weidhaas,et al.  Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  Donald Berry,et al.  Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 , 2006, Breast Cancer Research.

[96]  Robert Tibshirani,et al.  Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.

[97]  D. Dabbs,et al.  Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile , 2006, Modern Pathology.

[98]  M. J. van de Vijver,et al.  Classification of ductal carcinoma in situ by gene expression profiling , 2006, Breast Cancer Research.

[99]  J. Reis-Filho,et al.  Basal-like breast cancer and the BRCA1 phenotype , 2006, Oncogene.

[100]  Lajos Pusztai,et al.  Molecular classification of breast cancer: limitations and potential. , 2006, The oncologist.

[101]  Raymond R Tubbs,et al.  Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR , 2006, The American journal of surgical pathology.

[102]  A. Nobel,et al.  Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .

[103]  A. Ashworth,et al.  EGFR amplification and lack of activating mutations in metaplastic breast carcinomas , 2006, The Journal of pathology.

[104]  Yudi Pawitan,et al.  Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients , 2006, Breast Cancer Research.

[105]  S. Lakhani,et al.  Metaplastic breast carcinomas are basal‐like tumours , 2006, Histopathology.

[106]  A. Ashworth,et al.  Basal-like breast carcinomas: clinical outcome and response to chemotherapy , 2006, Journal of Clinical Pathology.

[107]  D. Easton,et al.  Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast , 2006, Histopathology.

[108]  W. Gerald,et al.  An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen , 2006, Oncogene.

[109]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[110]  S. Schnitt,et al.  Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer , 2006, Modern Pathology.

[111]  Daniel Birnbaum,et al.  Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. , 2006, Cancer research.

[112]  Robin L. Jones,et al.  Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis , 2006, Modern Pathology.

[113]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[114]  J. Benítez,et al.  Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer , 2006, Breast Cancer Research and Treatment.

[115]  J. Benítez,et al.  Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas , 2006, Clinical Cancer Research.

[116]  C. Perou,et al.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.

[117]  C. Perou,et al.  AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. , 2005, The Journal of clinical investigation.

[118]  F. Schmitt,et al.  P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ , 2006, Virchows Archiv.

[119]  A. Vincent-Salomon,et al.  KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome , 2005, Modern Pathology.

[120]  D. Birnbaum,et al.  Typical medullary breast carcinomas have a basal/myoepithelial phenotype , 2005, The Journal of pathology.

[121]  C. Caldas,et al.  Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[123]  A. Ashworth,et al.  Targeting the DNA repair defect of BRCA tumours. , 2005, Current opinion in pharmacology.

[124]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[125]  David Cameron,et al.  Identification of molecular apocrine breast tumours by microarray analysis , 2005, Oncogene.

[126]  A. Rosenberg,et al.  Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: A single-institution compilation compared with the National Cancer Institute SEER database , 2005 .

[127]  L. Bégin,et al.  Placental Cadherin and the Basal Epithelial Phenotype of BRCA1-Related Breast Cancer , 2005, Clinical Cancer Research.

[128]  Peter Devilee,et al.  Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. , 2005, Cancer research.

[129]  I. Bedrosian.  The prognostic implication of the basal-like (cyclin Ehigh/ p27low/p53+glomeruloid-microvascular-proliferation +) phenotype of BRCA1-related breast cancer , 2005 .

[130]  J. Cigudosa,et al.  Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers , 2005, Breast Cancer Research and Treatment.

[131]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[132]  Jorge S. Reis-Filho,et al.  Molecular Cytogenetic Identification of Subgroups of Grade III Invasive Ductal Breast Carcinomas with Different Clinical Outcomes , 2004, Clinical Cancer Research.

[133]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[134]  I. Ellis,et al.  Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.

[135]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[136]  L. Bégin,et al.  The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer , 2004, Cancer Research.

[137]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[138]  C. Reynolds,et al.  Microglandular Adenosis With Transition Into Adenoid Cystic Carcinoma of the Breast , 2003, The American journal of surgical pathology.

[139]  B. Gusterson,et al.  Distinct Genetic and Epigenetic Changes in Medullary Breast Cancer , 2003, International journal of surgical pathology.

[140]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[141]  Marcel J T Reinders,et al.  Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. , 2002, Cancer research.

[142]  M. King,et al.  BRCA1 transcriptionally regulates genes involved in breast tumorigenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[143]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[144]  G. Casey,et al.  Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers , 2001, Molecular pathology : MP.

[145]  G. Casey,et al.  Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[146]  P. J. Welch,et al.  Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[147]  G. Bratthauer,et al.  Carcinoma Arising in Microglandular Adenosis: An Immunohistochemical Analysis of 20 Intraepithelial and Invasive Neoplasms , 2000, International journal of surgical pathology.

[148]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[149]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[150]  S. Hirohashi,et al.  Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. , 2000, The American journal of surgical pathology.